Literature DB >> 15961791

A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration.

Mitsuaki Ishihara1, Takeshi Kujiraoka, Tadao Iwasaki, Makoto Nagano, Mayumi Takano, Jun Ishii, Masahiro Tsuji, Hajime Ide, Irina P Miller, Norman E Miller, Hiroaki Hattori.   

Abstract

Apolipoprotein A-V (apoA-V) is a recently discovered apolipoprotein that appears to have a role in plasma triglyceride (TG) transport. We have developed an ELISA for apoA-V using monoclonal antibodies that has a lower limit of detection of 0.3 ng/ml and linearity up to 20 ng/ml. The ELISA was then used to quantify plasma apoA-V in 196 healthy subjects and 106 patients with insulin-resistant diabetes mellitus. In the healthy subjects, total apoA-V concentration was 179.2 +/- 74.8 ng/ml, and it was greater in females than in males (P < 0.005). It was correlated positively with the plasma HDL cholesterol (r = 0.32, P < 0.0001), apoA-I (r = 0.27, P = 0.0001), and apoE (r = 0.18, P = 0.011) concentrations and negatively with plasma TG concentration (r = -0.22, P = 0.021). In relation to single nucleotide polymorphism 3 (-1131C/T) of the apoA-V gene, apoA-V concentration was higher in the T/T type than in the C/C type (P < 0.01). Plasma TG concentration was lower in the T/T type than in the C/C or C/T type (P < 0.05). ApoA-V concentration was lower in the diabetic patients (69.4 +/- 44.3 ng/ml; P < 0.01) than in the healthy controls.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961791     DOI: 10.1194/jlr.D500018-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  26 in total

1.  Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.

Authors:  G M Dallinga-Thie; A van Tol; H Hattori; L C van Vark-van der Zee; H Jansen; E J G Sijbrands
Journal:  Diabetologia       Date:  2006-04-28       Impact factor: 10.122

2.  An APOA5 3' UTR variant associated with plasma triglycerides triggers APOA5 downregulation by creating a functional miR-485-5p binding site.

Authors:  Cyrielle Caussy; Sybil Charrière; Christophe Marçais; Mathilde Di Filippo; Agnès Sassolas; Mireille Delay; Vanessa Euthine; Audrey Jalabert; Etienne Lefai; Sophie Rome; Philippe Moulin
Journal:  Am J Hum Genet       Date:  2014-01-02       Impact factor: 11.025

3.  Aberrant hetero-disulfide bond formation by the hypertriglyceridemia-associated p.Gly185Cys APOA5 variant (rs2075291).

Authors:  Vineeta Sharma; Andrzej Witkowski; H Ewa Witkowska; Andrew Dykstra; Jens B Simonsen; Lisa Nelbach; Jennifer A Beckstead; Clive R Pullinger; John P Kane; Mary J Malloy; Gordon Watson; Trudy M Forte; Robert O Ryan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-08-14       Impact factor: 8.311

4.  The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II.

Authors:  P J Talmud; J A Cooper; H Hattori; I P Miller; G J Miller; S E Humphries
Journal:  Diabetologia       Date:  2006-08-18       Impact factor: 10.122

5.  A single nucleotide polymorphism in APOA5 determines triglyceride levels in Hong Kong and Guangzhou Chinese.

Authors:  Chao Qiang Jiang; Bin Liu; Bernard M Y Cheung; Tai Hing Lam; Jie Ming Lin; Ya Li Jin; Xiao Jun Yue; Kwok Leung Ong; Sidney Tam; Ka Sing Wong; Brian Tomlinson; Karen S L Lam; G Neil Thomas
Journal:  Eur J Hum Genet       Date:  2010-06-23       Impact factor: 4.246

6.  Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats.

Authors:  B Dorfmeister; S Brandlhofer; F G Schaap; M Hermann; C Fürnsinn; B P Hagerty; H Stangl; W Patsch; W Strobl
Journal:  Diabetologia       Date:  2006-03-29       Impact factor: 10.122

7.  Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide.

Authors:  Toshihiro Sakurai; Akiko Sakurai; Boris L Vaisman; Marcelo J Amar; Chengyu Liu; Scott M Gordon; Steven K Drake; Milton Pryor; Maureen L Sampson; Ling Yang; Lita A Freeman; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2015-11-16       Impact factor: 4.030

8.  Association of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men.

Authors:  Yae Jung Hyun; Yangsoo Jang; Jey Sook Chae; Ji Young Kim; Jean Kyung Paik; So Yeon Kim; Ju Young Yang; Jose M Ordovas; Young Guk Ko; Jong Ho Lee
Journal:  Atherosclerosis       Date:  2008-12-31       Impact factor: 5.162

9.  The ins (cell) and outs (plasma) of apolipoprotein A-V.

Authors:  Trudy M Forte; Xiao Shu; Robert O Ryan
Journal:  J Lipid Res       Date:  2008-12-02       Impact factor: 5.922

10.  Determinants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans.

Authors:  P Hahne; F Krempler; F G Schaap; S M Soyal; H Höffinger; K Miller; H Oberkofler; W Strobl; W Patsch
Journal:  J Intern Med       Date:  2008-06-03       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.